UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 288

Sortiert nach

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Leukemia, 2020-11, Vol.34 (11), p.2837-2839

2020

Volltextzugriff (PDF)

The renaissance of interferon therapy for the treatment of myeloid malignancies

Blood, 2011-05, Vol.117 (18), p.4706-4715

2011

Volltextzugriff (PDF)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica (Roma), 2015-09, Vol.100 (9), p.1139

2015

Volltextzugriff (PDF)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of hematology and oncology, 2017-09, Vol.10 (1), p.156-6, Article 156

2017

Volltextzugriff (PDF)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Haematologica (Roma), 2021-03, Vol.106 (3), p.863

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Blood, 2012-12, Vol.120 (25), p.4921-4928

2012

Volltextzugriff (PDF)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica (Roma), 2019-08, Vol.104 (8), p.1580

2019

Volltextzugriff (PDF)

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Blood, 2019-02, Vol.133 (8), p.790-794

2019

Volltextzugriff (PDF)

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Blood, 2013-06, Vol.121 (23), p.4778-4781

2013

Volltextzugriff (PDF)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.135-135, Article 135

2021

Volltextzugriff (PDF)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

Haematologica (Roma), 2018-01, Vol.103 (1), p.51

2018

Volltextzugriff (PDF)

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Haematologica (Roma), 2015-09, Vol.100 (9), p.1117

2015

Volltextzugriff (PDF)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Haematologica (Roma), 2024-02, Vol.109 (2), p.676

2024

Volltextzugriff (PDF)

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Blood, 2009-05, Vol.113 (20), p.4829-4833

2009

Volltextzugriff (PDF)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Haematologica (Roma), 2023-07, Vol.108 (7), p.1960

2023

Volltextzugriff (PDF)

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses

Haematologica (Roma), 2020-03, Vol.105 (3), p.e95

2020

Volltextzugriff (PDF)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

Blood cancer journal (New York), 2018-10, Vol.8 (10), p.94-6, Article 94

2018

Volltextzugriff (PDF)

Myeloproliferative neoplasms and personalized medicine: the perfect match?

Haematologica (Roma), 2015-12, Vol.100 (12), p.1493

2015

Volltextzugriff (PDF)

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

International journal of molecular sciences, 2021-03, Vol.22 (7), p.3530

2021

Volltextzugriff (PDF)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms

Blood cancer journal (New York), 2024-01, Vol.14 (1), p.1-1, Article 1

2024

Volltextzugriff (PDF)

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Haematologica (Roma), 2012-10, Vol.97 (10), p.1570-1573

2012

Volltextzugriff (PDF)

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project

Biomedicines, 2023-07, Vol.11 (7), p.1925

2023

Volltextzugriff (PDF)

1 – 25 von 288

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(283)
Mit Volltextzugriff
(275)

Publikationsform

Artikel
(287)
Webseiten
(1)

Sprache

Englisch
(288)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(76)
Life Sciences & Biomedicine
(74)
Hematology
(69)
Humans
(65)
Female
(27)
Male
(27)
Life Sciences
(22)
Middle Aged
(22)
Mutation
(22)
Biological And Medical Sciences
(19)
Hematologic And Hematopoietic Diseases
(19)
Medical Sciences
(19)
Adult
(18)
Oncology
(17)
Aged
(16)
Janus Kinase 2 - Genetics
(16)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(16)
Polycythemia Vera - Genetics
(12)
Myeloproliferative Disorders - Genetics
(11)
Primary Myelofibrosis - Drug Therapy
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

The renaissance of interferon therapy for the treatment of myeloid malignancies

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

Myeloproliferative neoplasms and personalized medicine: the perfect match?

ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera-Advanced Integrated Models (PV-AIM) Project

Aktive Filter

Suchergebnisse filtern